✦ LIBER ✦

Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer

✍ Scribed by Emel Yaman; Aytug Uner; Ozlem Er; Ugur Coskun; Suleyman Buyukberber; Mustafa Dikilitas; Mevlude Polat; Deniz Yamac; Ali Osman Kaya; Ramazan Yildiz; Banu Ozturk; Mustafa Benekli; for Anatolian Society of Medical Oncology (ASMO)

Book ID: 107576613
Publisher: Springer US
Year: 2007
Tongue: English
Weight: 140 KB
Volume: 24
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-007-0035-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of capecitabine plus oxal

Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer

✍ Yu Hong Li; Hui Yan Luo; Feng Hua Wang; Zhi Qiang Wang; Miao Zhen Qiu; Yan Xia S 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 234 KB

Chronomodulated administration of oxalip

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

✍ Daniele Santini; Bruno Vincenzi; Gaia Schiavon; Marisa Di Seri; Vladimir Virzí; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 328 KB

Chemotherapy for the Treatment of Patien

Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An Overview

✍ William H. Isacoff; Katrina Borud 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 310 KB

Randomised trial comparing biweekly oxal

Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401

✍ Pasquale Comella; Bruno Massidda; Gianfranco Filippelli; Antonio Farris; Donato 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 475 KB

Out-of-pocket payment and cost-effective

Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan

✍ Takeru Shiroiwa; Takashi Fukuda; Kiichiro Tsutani 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 595 KB

Capecitabine plus oxaliplatin for the fi

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma : Final results of the Southern Italy Cooperative Oncology Group Trial 0108

✍ Pasquale Comella; Donato Natale; Antonio Farris; Antonio Gambardella; Luigi Maio 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB

## Abstract ## BACKGROUND In patients with metastatic colorectal carcinoma (MCC), capecitabine has demonstrated a superior response rate (RR), equivalent disease progression‐free (PFS) and overall survival (OS), and an improved overall tolerability profile compared with bolus 5‐fluorouracil/leucov